This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Not just for the prevention of heartdisease but also to reduce your risk of dying from all conditions. The relationship is simple—higher cholesterol for longer increases your risk of coronaryarterydisease 4. If you have a family history of heartdisease, this is a must-do test.
Cleerly, a digital healthcare company focused on heartdisease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal CardiovascularImaging. Eur Heart J Cardiovasc Imaging.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
With this new funding, Cleerly will continue to scale its commercial growth and clinical evidence generation, helping health care professionals improve outcomes for patients across the coronary care pathway. Barclay continued, “Cardiovasculardisease is the #1 cause of death globally and costs our country $422B annually.
If you have an early family history of heartdisease, there are specific steps you need to take to define if you have an increased risk and what to do about it. Heartdisease is the leading cause of death worldwide, and the probability of someone in your family having heartdisease is likely to be high.
The majority of heart attacks occur as a result of plaque in the coronaryarteries that is not obstructive and, therefore, asymptomatic. 2 You will not know you have heartdisease by waiting for symptoms. mmol/l (130 mg/dl) or below, between 20-50% will already have coronaryarterydisease.
Planners have designed this year’s program and events to engage physicians, trainees, technologists and healthcare professionals in a complete overview of the cardiovascular CT field. A Welcome Reception will close out the day in the exhibit hall from 6:00 p.m. - for all attendees.
Christian Tesche (Division of CardiovascularImaging, Department of Radiology and Radiological Science, Medical University of South Carolina and Department of Cardiology, Munich University Clinic, Ludwig-Maximilian-University).
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heartdisease, shared findings from a study published online in the Journal of the American College of Cardiology: CardiovascularImaging on March 13, 2024.
milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heartdisease, announced that its recently U.S. Derivation, Validation and Prognostic Assessment of an AI-Based Algorithm for Determination of Coronary Ischemia: The CREDENCE and PACIFIC Trial.
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
a leader in non-invasive artificial intelligence (AI) heart care solutions, announced that the data from its REVEALPLAQUE study , highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal CardiovascularImaging. 1 Heartdisease is the leading cause of death for both men and women.²
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content